ORIC Pharmaceuticals To Share Combination Dose Optimization Data From Phase 1b Study Of Rinzimetostat In Participants With Metastatic Castration Resistant Prostate Cancer

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) will present combination dose optimization data from its Phase 1b trial of rinzimetostat (ORIC-944) for metastatic castration resistant prostate cancer (mCRPC) during a conference call and webcast scheduled for March 31, 2026, at 4:30pm ET.